Lenz Therapeutics Earnings Call: High Spend, Growing Traction

Lenz Therapeutics, Inc. ((LENZ)) has held its Q4 earnings call. Read on for the main highlights of the call.

Lenz Therapeutics struck a cautiously optimistic tone on its latest earnings call, highlighting strong early signs that its presbyopia drop is resonating with doctors and patients despite steep launch-phase losses. Management framed the quarter as an investment period, betting that high awareness, promising unit economics and a solid cash cushion will support a scaled commercial ramp over coming quarters.

Real-World Efficacy Underpins Product Confidence

Patients are reportedly seeing near-vision improvement within about 30 minutes of use, with benefits lasting through the workday. Early refill patterns and persistence are described as encouraging, giving management confidence that once patients try the product, they are likely to continue using it.

Early Commercial Traction in Units and Prescribers

From launch through quarter-end, Lenz expects to have sold more than 45,000 monthly packs, with net product revenue of roughly $1.6 million in the first quarter of launch. Over 20,000 monthly paid and filled prescriptions and more than 10,000 prescribing eye care professionals point to a broad base of early adopters.

High Prescriber Productivity Among Early Adopters

The top 1,000 prescribers are already writing over 40% more scripts per doctor than at a comparable stage of the competing VUITY launch. More than 55% of doctors who have tried VIZZ have written it multiple times, signaling strong productivity and repeat use among early enthusiasts.

Physician Awareness and Enrollment Already Very High

Aided awareness among eye care professionals is about 98%, with unaided awareness near 79%, an unusually high level for an early launch. Lenz has enrolled more than 14,000 eye care locations, including many physicians who never prescribed the prior market entrant.

Sales Force Expansion Broadens Field Coverage

The company is expanding its field organization from 88 to 117 representatives, adding 29 to deepen reach and frequency. Management expects this expanded team to cover roughly 15,000 eye care professionals, positioning the brand to reach a larger share of the U.S. presbyope market.

DTC Campaign Shows Strong Early Engagement

A direct-to-consumer campaign launched in mid-January has driven website traffic to about five times baseline, with spikes reaching ten times during national pushes. YouTube brand lift is running around double benchmark levels, and key digital metrics such as click-through rates and cost per impression are outperforming relevant comps.

Cash-Rich Balance Sheet Supports Investment Phase

Lenz ended the fiscal year with about $292.3 million in cash, cash equivalents and marketable securities and carries no debt. This provides meaningful runway to fund sales, marketing and category-building efforts even as the company posts substantial operating losses.

Solid Revenue Per Unit and Gross-to-Net Dynamics

The company reported a blended gross-to-net ratio near 90%, translating to roughly $67 per monthly package. Management expects net cash per unit of about $60 per pack, broadly in line with internal models and supportive of the brand’s long-term economic potential.

Advancing Global Regulatory Footprint

Lenz has completed five ex-U.S. regulatory submissions, including an NDA in China and filings in South Korea, Thailand, Singapore and with the EMA. The company expects to exceed 10 submissions by year-end, with potential approvals in multiple international markets targeted for 2027.

R&D Spend Falls as Late-Stage Programs Conclude

Research and development expense dropped to zero in the fourth quarter, versus $5.9 million a year earlier. The decline reflects completion of Phase III CLARITY studies and approval, reducing near-term development outlays on the income statement.

Heavy Operating Costs Drive Wider Net Loss

Fourth-quarter operating expenses reached about $40 million, largely driven by $39.6 million in SG&A. That spending helped push the net loss to $35.9 million, up roughly 183% from the prior-year quarter, with loss per share rising to $1.16 from $0.46.

Rapid SG&A Build to Support Launch Infrastructure

Selling, general and administrative costs surged about 321% year over year, from $9.4 million to $39.6 million. Sequentially, SG&A climbed roughly 43% as Lenz funded its sales force buildout and the national DTC launch that underpin its category-creation strategy.

Material Cash Burn as Marketing Takes Priority

Net cash burn in the fourth quarter was approximately $32 million, reflecting the capital intensity of the launch. Management signaled that sales and marketing will remain 75–80% of operating expenses in the near term, keeping burn elevated even as revenues grow.

Gradual NRx Ramp Amid Category Building

New patient starts are developing more slowly than some prior launches as Lenz emphasizes sampling and physician education to build a new treatment category. Management expects that sales force expansion and maturing DTC efforts will require roughly two quarters before materially lifting prescription volumes.

Limited Early Visibility on Refills and Conversion

The company is not yet disclosing concrete refill rates, sample-to-script conversions or detailed mix between one-month and three-month packs. Executives say these metrics should become clearer after more quarters of sales data, leaving some uncertainty for near-term modeling.

Low Direct Product Gross Margin Raises Questions

Fourth-quarter cost of goods sold was about $400,000, and management expects direct product gross margin to trend near 9%. Such a low margin constrains per-unit gross profit and suggests Lenz will need scale, mix improvements or pricing to enhance profitability over time.

Execution Risk in Changing Prescribing Behavior

Many eye care professionals still view the drops as suitable mainly for early presbyopes, limiting initial reach. Lenz must reframe the conversation and embed a quick, roughly 10-second exam dialogue to broaden inclusion, making physician education a key execution swing factor.

Uncertain Timing for DTC-Driven Prescription Lift

While early DTC metrics are promising, management cautioned that it often takes at least two quarters for consumer campaigns to translate into prescriptions. At this stage, the company has not firmly established a correlation between digital traffic and script growth, adding timing uncertainty.

Guidance Points to Gradual Acceleration Ahead

Looking forward, Lenz is guiding toward an acceleration in new patient starts as its enlarged sales force, sampling strategy and DTC campaign mature. Management is leaning on strong awareness, favorable unit economics, more than 45,000 packs sold and expanding global submissions to argue the business can scale despite current cash burn and low gross margin.

Lenz Therapeutics’ call painted the picture of a high-potential, high-spend launch still in its early innings. For investors, the story now hinges on whether strong physician engagement, growing prescription volume and disciplined use of its sizeable cash balance can eventually overcome thin margins and heavy SG&A to deliver sustainable growth.